论文部分内容阅读
目的:观察慈丹胶囊联合肝动脉化疗栓塞术(TACE)在中、晚期原发性肝癌综合治疗中的作用。方法:将121例中、晚期原发性肝癌患者随机分为2组:联合组64例,采用慈丹胶囊(每次5粒,每日4次)联合TACE治疗;对照组57例,单纯采用TACE治疗。对2组的有效率、生存率、生活质量和免疫功能进行比较评价。结果:治疗后联合组的有效率、1a生存率、甲胎蛋白下降程度均显著高于对照组(P<0.05);联合组的生活质量提高水平显著高于对照组(P<0.01);联合组的T细胞亚群及NK细胞活性显著高于对照组(P<0.01)。结论:慈丹胶囊联合TACE可以提高中、晚期肝癌的疗效和1a生存率,并改善细胞免疫功能,从而提高患者的生活质量。
Objective: To observe the effect of Cidan capsule combined with transcatheter arterial chemoembolization (TACE) in the comprehensive treatment of primary and primary liver cancer. Methods: A total of 121 patients with primary and primary liver cancer were randomly divided into two groups: 64 cases in combination group and 5 cases in CC group (5 capsules, 4 times a day) combined with TACE. Control group, 57 cases, TACE treatment. The two groups of efficiency, survival, quality of life and immune function were compared. Results: The effective rate, 1a survival rate and the decline of alpha-fetoprotein in the combined group after treatment were significantly higher than those in the control group (P <0.05); the quality of life in the combination group was significantly higher than that in the control group (P <0.01) The T cell subsets and NK cell activity of the group were significantly higher than those of the control group (P <0.01). Conclusion: Cidan capsule combined with TACE can improve the curative effect of middle and advanced liver cancer and 1a survival rate, and improve cellular immune function, so as to improve the quality of life of patients.